ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2462

Centrosomal Protein 70kDa Is Down-Regulated By Decoy Receptor 3 in Specifically Rheumatoid Synovial Fibroblasts

Koji Fukuda1,2, Yasushi Miura2,3, Toshihisa Maeda2, Shinya Hayashi2 and Masahiro Kurosaka2, 1Orthopaedic Surgery, Kakogawa City Hospital, Kakogawa, Japan, 2Orthopaedic Surgery, Kobe University Graduate School of Medicine, Kobe, Japan, 3Rehabilitation Science, Kobe University Graduate School of Health Sciences, Kobe, Japan

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: cytokines, rheumatoid arthritis (RA) and synovial cells, synovial fluid

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Rheumatoid Arthritis - Human Etiology and Pathogenesis

Session Type: Abstract Submissions (ACR)

Background/Purpose: Decoy receptor 3 (DcR3) is a secreted decoy tumor necrosis factor receptor and competitively binds and inhibits the TNF family including Fas-ligand, LIGHT, and TL1A. DcR3 is overexpressed in tumor cells and might benefit tumors by helping them to avoid cytotoxic and regulatory effects of the ligands. We previously reported that DcR3 overexpressed in rheumatoid synovial fibroblasts (RA-FLS) stimulated by TNFα protects the cells from Fas-induced apoptosis [1]. We recently reported that DcR3 binds to TL1A expressed on RA-FLS resulting in the negative regulation of cell proliferation induced by inflammatory cytokines [2]. Further, we newly revealed the gene expression profiles in RA-FLS regulated by DcR3 by using microarray data analysis. The profiles indicated centrosomal protein 70kDa (Cep70) was down-regulated by DcR3 (fold change 1.87) [3]. Centrosome forms the backbone of cell cycle progression mechanism. Further, CEP family protein is the active component of centrosome and plays a vital role in centriole biogenesis and cell cycle progression control [4]. In this study, we studied Cep70 as one of the key molecules in DcR3-TL1A signaling in RA-FLS based on the genes expression profiles regulated by DcR3.

Methods: Real-time polymerase chain reaction (real-time PCR). RA and osteroarthritis (OA) -FLS were stimulated with 1ng/ml of recombinant human TNFα or IgG1 for 24 hours, or with various concentration of DcR3-Fc or control IgG1 for 12 hours. Further, RA-FLS were incubated with DcR3-Fc for 12 hours after overnight pre-incubation with anti-TL1A antibody. The relative expression levels of Cep70 mRNA were quantified by real-time PCR.

Immunohistochemistry. Anti-Cep70 antibody was applied to frozen sections of synovial tissues from patients with RA or OA for over night. Sections were stained with HistoFine simple stain Kit and DAB chromogen, followed by counterstaining with hematoxylin.

Results: Real-time PCR revealed that the expression of Cep70 mRNA in RA-FLS was higher than that in OA-FLS and that TNFα significantly decreased the expression of Cep70 mRNA in RA and OA-FLS (RA, 51%; OA, 59%). DcR3-Fc also significantly decreased the expression of Cep70 mRNA in RA-FLS in a dose dependent manner (81% with 10ng/ml, 73% with 100ng/ml, and 57% with 1000ng/ml). In contrast, DcR3-Fc did not decrease Cep70 mRNA in OA-FLS. Anti-TL1A antibody inhibited the down-regulation of Cep70 expression in RA-FLS induced by DcR3-Fc. Immunohistochemistry revealed that Cep70 protein was expressed more in superficial lining layer of rheumatoid synovium than that of OA synovium.

Conclusion: In this study, we revealed that Cep70 was increased in RA-FLS and that the expression of Cep70 in RA-FLS was decreased by DcR3 by binding to membrane-bound TL1A in a disease-specific fashion . DcR3 may affect the pathogenesis of RA through Cep70.

References: 1. Hayashi S. et al., Arthritis and Rheum, 56,1067-1074,2007

2. Takahashi M. et al., Int J Mol Med, 28,423-427,2011

3. Fukuda K. et al., Int J Mol Med, 32,910-916,2013

4. Kumar A. et al., Protoplasma, 250,965-983,2013.


Disclosure:

K. Fukuda,
None;

Y. Miura,
None;

T. Maeda,
None;

S. Hayashi,
None;

M. Kurosaka,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/centrosomal-protein-70kda-is-down-regulated-by-decoy-receptor-3-in-specifically-rheumatoid-synovial-fibroblasts/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology